Companies agree to pay $110M settlement for PFAS chemicals in Ohio
The Chemours Co. (CC) said Wednesday it reached a settlement with the State of Ohio along with DuPont de Nemours Inc. (DD) and Corteva Inc. (CTVA) for $110 million to resolve claims related to the manufacture and sale of per- and polyfluoroalkyl substances (PFAS). The agreement resolves Ohio's PFAS claims from the companies' facilities including the Washington Works plant along the Ohio-West Virginia border. Chemours will pay 50% of the settlement costs, or $55 million, while DuPont and Corteva will be responsible for the remaining 50%. "Chemours believes this settlement furthers its objective to manage and resolve legacy liabilities," the company said. Chemours stock was up by 1.4% in premarket trading. DuPont's stock has risen 3.4% so far in 2023, compared to an 18.6% increase by the S&P 500 .
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
11-29-23 0715ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Coinbase Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy
-
Energy Transfer Earnings: M&A Drives Guidance Increase In Solid Quarter
-
The Best Healthcare Stocks to Buy
-
Going Into Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?
-
Arm Earnings: Shares Fall as 2025 Guidance Disappoints Investors